172 related articles for article (PubMed ID: 37345045)
1. Sex-Specific Associations of
Ward SV; Autuori I; Luo L; LaPilla E; Yoo S; Sharma A; Busam KJ; Olilla DW; Dwyer T; Anton-Culver H; Zanetti R; Sacchetto L; Cust AE; Gallagher RP; Kanetsky PA; Rosso S; Begg CB; Berwick M; Thomas NE; Orlow I;
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345045
[No Abstract] [Full Text] [Related]
2. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study.
Tripon F; Iancu M; Trifa A; Crauciuc GA; Boglis A; Balla B; Cosma A; Dima D; Candea M; Lazar E; Jimbu L; Banescu C
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492903
[TBL] [Abstract][Full Text] [Related]
3. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Gansmo LB; Romundstad P; Birkeland E; Hveem K; Vatten L; Knappskog S; Lønning PE
Cancer Med; 2015 Dec; 4(12):1901-7. PubMed ID: 26471763
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
5. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
6. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.
Wu CC; Krahe R; Lozano G; Zhang B; Wilson CD; Jo EJ; Amos CI; Shete S; Strong LC
Hum Genet; 2011 Jun; 129(6):663-73. PubMed ID: 21305319
[TBL] [Abstract][Full Text] [Related]
7. Specific allelic variants of SNPs in the
Bauer M; Kantelhardt EJ; Stiewe T; Nist A; Mernberger M; Politt K; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Wickenhauser C; Thomssen C; Bartel F; Vetter M
Oncotarget; 2019 Mar; 10(20):1975-1992. PubMed ID: 30956778
[TBL] [Abstract][Full Text] [Related]
8. Germline genetics of the p53 pathway affect longevity in a gender specific manner.
Groß S; Immel UD; Klintschar M; Bartel F
Curr Aging Sci; 2014; 7(2):91-100. PubMed ID: 24654968
[TBL] [Abstract][Full Text] [Related]
9. Associations of
Bartnykaitė A; Savukaitytė A; Ugenskienė R; Daukšaitė M; Korobeinikova E; Gudaitienė J; Juozaitytė E
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669778
[TBL] [Abstract][Full Text] [Related]
10. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
12. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
13. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
14. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
15. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.
Liu J; Tang X; Li M; Lu C; Shi J; Zhou L; Yuan Q; Yang M
Breast Cancer Res Treat; 2013 Jul; 140(1):151-7. PubMed ID: 23793604
[TBL] [Abstract][Full Text] [Related]
16. A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.
Zhang Y; Sturgis EM; Wei P; Liu H; Wang Z; Ma Y; Liu C; Gu KJ; Wei Q; Li G
Mol Carcinog; 2019 Dec; 58(12):2276-2285. PubMed ID: 31513313
[TBL] [Abstract][Full Text] [Related]
17. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
18.
Arnoff TE; El-Deiry WS
Am J Cancer Res; 2022; 12(5):2102-2117. PubMed ID: 35693093
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
20. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
